Cetuximab–Polymersome–Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cetuximab–Polymersome–Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers
Authors
Keywords
-
Journal
BIOMACROMOLECULES
Volume 23, Issue 1, Pages 100-111
Publisher
American Chemical Society (ACS)
Online
2021-12-16
DOI
10.1021/acs.biomac.1c01065
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Self-Guiding Polymeric Prodrug Micelles with Two Aggregation-Induced Emission Photosensitizers for Enhanced Chemo-Photodynamic Therapy
- (2021) Xiaoqing Yi et al. ACS Nano
- Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis
- (2021) Wen Xu et al. Aging-US
- Polyprodrug with Glutathione Depletion and Cascade Drug Activation for Multi-drug Resistance Reversal
- (2021) Xuan Xiao et al. BIOMATERIALS
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action
- (2021) Nishant Mohan et al. Cancers
- Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
- (2021) Emma-Anne Karlsen et al. Cells
- Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma
- (2021) Na Yu et al. ADVANCED MATERIALS
- Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control
- (2021) Phuoc Vinh Nguyen et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
- (2021) Mary Luz Uribe et al. Cancers
- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
- (2021) Paolo Tarantino et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer
- (2021) Yifan Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy
- (2020) Shi Gao et al. ACS Nano
- Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics
- (2020) Xi‐Le Hu et al. ADVANCED FUNCTIONAL MATERIALS
- First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors.
- (2020) Rui-hua Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis and Analysis of 64Cu-Labeled GE11-Modified Polymeric Micellar Nanoparticles for EGFR-Targeted Molecular Imaging in a Colorectal Cancer Model
- (2020) Igor Paiva et al. MOLECULAR PHARMACEUTICS
- Icaritin enhances the efficacy of cetuximab against triple‑negative breast cancer cells
- (2020) Li Yin et al. Oncology Letters
- GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma
- (2020) Cheng Zhou et al. Acta Biomaterialia
- Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
- (2020) Wenxing Gu et al. JOURNAL OF CONTROLLED RELEASE
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
- (2019) David M. Cognetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand‐Installed Nanocarriers toward Precision Therapy
- (2019) Peng Mi et al. ADVANCED MATERIALS
- Antibody therapeutics and immunoregulation in cancer and autoimmune disease
- (2019) Masahiro Yasunaga SEMINARS IN CANCER BIOLOGY
- HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor
- (2019) Lin Ding et al. BIOMACROMOLECULES
- In vitro elimination of EGFR‐overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab
- (2019) Sara Caratelli et al. INTERNATIONAL JOURNAL OF CANCER
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy
- (2019) Yu-Jen Lu et al. CHEMICAL ENGINEERING JOURNAL
- The advent and rise of monoclonal antibodies
- (2019) Klaus Rajewsky NATURE
- A Third Shot at EGFR: New Opportunities in Cancer Therapy
- (2019) Salvador Guardiola et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Hyaluronic Acid-Shelled Disulfide-Cross-Linked Nanopolymersomes for Ultrahigh-Efficiency Reactive Encapsulation and CD44-Targeted Delivery of Mertansine Toxin
- (2018) Yue Zhang et al. ACS Applied Materials & Interfaces
- Organocatalytic Ring-Opening Copolymerization of Trimethylene Carbonate and Dithiolane Trimethylene Carbonate: Impact of Organocatalysts on Copolymerization Kinetics and Copolymer Microstructures
- (2018) Jingjing Wei et al. BIOMACROMOLECULES
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer
- (2018) Wenyan Fu et al. MOLECULAR IMMUNOLOGY
- GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment
- (2018) Yan Zou et al. MOLECULAR PHARMACEUTICS
- EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis
- (2018) Francesco Agustoni et al. CANCER TREATMENT REVIEWS
- Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies
- (2018) Francesco Roncato et al. Nature Communications
- Peptide-decorated polymeric nanomedicines for precision cancer therapy
- (2018) Huanli Sun et al. JOURNAL OF CONTROLLED RELEASE
- αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
- (2017) Ping Zhong et al. International Journal of Nanomedicine
- Targeted cancer therapy through antibody fragments-decorated nanomedicines
- (2017) Abbas Alibakhshi et al. JOURNAL OF CONTROLLED RELEASE
- A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy
- (2017) Hao Meng et al. MACROMOLECULAR BIOSCIENCE
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy
- (2017) Hua Jin et al. Nanoscale
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy
- (2016) Ping Zhong et al. BIOMACROMOLECULES
- Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
- (2016) Yan Zou et al. JOURNAL OF CONTROLLED RELEASE
- Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
- (2016) Stephen R. Adams et al. Nature Communications
- EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer
- (2015) Goutam Mondal et al. BIOMACROMOLECULES
- In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer
- (2015) Rajaletchumy Veloo Kutty et al. BIOMATERIALS
- A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
- (2015) A. V. Yurkovetskiy et al. CANCER RESEARCH
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
- (2013) Chetan Yewale et al. BIOMATERIALS
- MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells
- (2013) Lumin Wang et al. BMC CANCER
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
- (2012) Christoph Mamot et al. LANCET ONCOLOGY
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started